News tagged with erlotinib

Related topics: lung cancer

Assessing positive outcomes of phase III trials

Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in ...

Dec 03, 2010
popularity0 comments 0

Economic analysis: Erlotinib marginally cost-effective

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally ...

Feb 16, 2010
popularity0 comments 0


Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed